CPORT-E: Comparison of percutaneous treatment cost in hospitals with and without central vascular surgery.

A total of 18,273 patients receiving angioplasty in hospitals with or without central vascular surgery were followed for 9 months and the costs were evaluated. Mortality and the occurrence of events were not different between the two groups. The cost of treatment was lower in the central vascular surgery centers (23,961 USD versus 25,540 USD, p = 0.02).

Conclusion: Coronary angioplasty in hospitals with central vascular surgery reduces costs.

Comment: The cost difference is probably related to the standby surgery centers having a greater volume and therefore more experience than smaller centers without surgery


Eric Eisenstein
2012-11-04

Original title: Economic Outcomes of Percutaneous Coronary Intervention Performed at Sites With and Without On-Site Cardiac Surgery.

 

More articles by this author

TACT trial: Chelation Therapy for the Treatment of Coronary Disease.

In theory, also as for certain diseases caused by mineral deposits, Chelation treatment with EDTA (Ethylene Diamine Tetra-Acetic Acid) could reduce calcium and cholesterol...

TRILOGY Trial: First large scale test evaluating platelet function in acute coronary syndromes.

TRILOGY ACS which was presented at the ESC 2012 is a randomized, double blind study that included 10,300 patients and compared aspirin + cloplidogrel...

FREEDOM trial: CABG versus angioplasty treatment for diabetic patients with multivessel disease

The trial included 1,900 patients followed for at least 2 years, (mean 3.8 years), randomized 1:1 to pharmacological angioplasty stents, (sirolimus or paclitaxel at...

Artic Study: Bedside Platelet Function Monitoring to Reduce Events after DES Implantation .

Given the individual variability of response to antiplatelet therapies, measuring platelet function and designing tailored therapies could be beneficial. The ARTIC study tested the superiority...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SAPIEN 3 TAVI Durability: Ten-Year Follow-Up in Intermediate-Risk Patients

The durability of transcatheter bioprosthetic valves used in TAVI remains one of the key unanswered questions as indications continue to expand toward patients with...

Aneurysm Sac Regression Predicts Better Clinical Outcomes After EVAR?

Aneurysm sac regression following endovascular abdominal aortic aneurysm repair (EVAR) has been proposed as a marker of favorable remodeling and effective aneurysm exclusion. However,...

Inflammation after TAVI: An Emerging Therapeutic Target?

Conduction disturbances and the need for permanent pacemaker implantation remain common complications following TAVI, with an incidence approaching 15%. Although they have traditionally been...